ArticleThe Journal of clinical investigation2021
Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis.
Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- Circulating Proteomics Identifies a Dynamic Profile of Hepatic Steatosis During Metabolic Intervention.Journal of the American Heart Association · 2025Trial
- Metabolic stress-activated endothelial STING rewires the sinusoidal immune niche to promote MASLD progression.The Journal of clinical investigation · 2026Article
- The GPX3-VCAM1 Axis Gates Pro-Fibrotic Tubule Cell Fate in Hyperuricemic Nephropathy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Endothelial cell glycogen synthase kinase 3β promotes lipotoxic endotheliopathy and liver inflammation in MASH.JCI insight · 2026Article
- Reticulocalbin 3 as a novel biomarker for assessing liver disease severity and identifying decompensated status in cirrhosis.Scientific reports · 2026Article
- When the Liver Flares: Inflammatory and Immunometabolic Mechanisms Driving the Transition from MASLD to MASH.Inflammation · 2026Review
- Sinusoidal endothelial cells control liver inflammation and fibrosis.The Journal of clinical investigation · 2026Article
- Toxic lipid-induced epigenetic activation of ICAM1 in liver sinusoidal endothelium regulates myeloid-driven fibro-inflammatory response in MASH.Hepatology (Baltimore, Md.) · 2026Article
- Liver sinusoidal endothelial TGF-β signaling accelerates partial endothelial-mesenchymal transition and MASH through Notch.JHEP reports : innovation in hepatology · 2026Article
- Lack of GPNMB Is Associated With Altered Lipid and Glucose Metabolism and Disrupted Diurnal Hepatic Glycogen Regulation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Abnormalities of liver sinusoidal endothelial cells in primary biliary cholangitis.World journal of experimental medicine · 2026Article
- Endothelial Cell Therapy for the Acute and Chronic Liver Disease.Seminars in liver disease · 2026Review
- Simvastatin Ameliorates Lipid Metabolism-Mediated Endothelial Inflammation and Tight Junction Impairment in Chronic Cerebral Hypoperfusion.Neuromolecular medicine · 2026Article
- Association between the C-reactive protein-triglyceride-glucose index and coronary heart disease in metabolic dysfunction-associated steatotic liver disease patients: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH).Drug design, development and therapy · 2026Review
- Hepatic Arterial Flow-Induced Portal Tract Fibrosis in Portal Hypertension: The Role of VCAM-1 and Osteopontin-Expressing Macrophages.Cellular and molecular gastroenterology and hepatology · 2026Article
- VCAM-1 and Osteopontin Link Hemodynamic Alteration to Fibrosis in Portal Hypertension.Cellular and molecular gastroenterology and hepatology · 2026Article
- Daixie recipe ameliorates diet-induced MASH in miceFrontiers in endocrinology · 2026Article
- E-Selectin-Targeted Nanomicelles via Sialic Acid Conjugation for Anti-Inflammatory Efficacy and Alleviating the Progression of Metabolic-Associated Steatotic Liver Disease.Biomaterials research · 2026Article
- Role of miRNA signalling in the pathogenesis of MASLD.Frontiers in pharmacology · 2026Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
Monocyte homing to the liver and adhesion to the liver sinusoidal endothelial cells (LSECs) are key elements in nonalcoholic steatohepatitis (NASH) pathogenesis. We reported previously that VCAM-1 mediates monocyte adhesion to LSECs. However, the pathogenic role of VCAM-1 in NASH is unclear. Herein, we report that VCAM-1 was a top upregulated adhesion molecule in the NASH mouse liver transcriptome. Open chromatin landscape profiling combined with genome-wide transcriptome analysis showed robust transcriptional upregulation of LSEC VCAM-1 in murine NASH. Moreover, LSEC VCAM-1 expression was significantly increased in human NASH. LSEC VCAM-1 expression was upregulated by palmitate treatment in vitro and reduced with inhibition of the mitogen-activated protein 3 kinase (MAP3K) mixed lineage kinase 3 (MLK3). Likewise, LSEC VCAM-1 expression was reduced in the Mlk3-/- mice with diet-induced NASH. Furthermore, VCAM-1 neutralizing Ab or pharmacological inhibition attenuated diet-induced NASH in mice, mainly via reducing the proinflammatory monocyte hepatic population as examined by mass cytometry by time of flight (CyTOF). Moreover, endothelium-specific Vcam1 knockout mice were also protected against NASH. In summary, lipotoxic stress enhances the expression of LSEC VCAM-1, in part, through MLK3 signaling. Inhibition of VCAM-1 was salutary in murine NASH and might serve as a potential therapeutic strategy for human NASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.